Cargando…
Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology, with great success in the treatment of COVID-19. They have been used massively worldwide. One of the major inconveniences of these vaccines is...
Autores principales: | Hermosilla, Jesús, Alonso-García, Airan, Salmerón-García, Antonio, Cabeza-Barrera, José, Medina-Castillo, Antonio L., Pérez-Robles, Raquel, Navas, Natalia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675537/ https://www.ncbi.nlm.nih.gov/pubmed/38005967 http://dx.doi.org/10.3390/vaccines11111635 |
Ejemplares similares
-
Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation
por: Hermosilla, Jesús, et al.
Publicado: (2020) -
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
por: Navas, Natalia, et al.
Publicado: (2020) -
Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress
por: Torrente-López, Anabel, et al.
Publicado: (2022) -
Robust induction of neutralizing antibodies against the SARS‐CoV‐2 Delta variant after homologous Spikevax or heterologous Vaxzevria‐Spikevax vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2022) -
L’EMA recommande la booster dose avec Spikevax
por: Manus, Jean-Marie
Publicado: (2022)